Related Experiment Video

Updated: Jul 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges

Laura L Rokosz1, James R Beasley, Carolyn Diianni Carroll

  • 1Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543-5350, USA.

Expert Opinion on Therapeutic Targets
|June 17, 2008
PubMed

Insights

Kinase inhibitors, initially developed for cancer, show promise for immune and inflammatory diseases. Greater target selectivity is crucial for effectively treating these chronic conditions.

Area of Science:

  • Pharmacology
  • Immunology
  • Oncology

Background:

  • Seven kinase inhibitor drugs are currently marketed, with the first, imatinib mesilate, approved in 2001.
  • Approved kinase inhibitors target kinases like BCR/ABL, PDGF receptor, c-kit, c-SRC, and Bruton's tyrosine kinase.
  • Current applications of kinase inhibitors are primarily in oncology, demonstrating achievable target selectivity within the kinome.

Purpose of the Study:

  • To review the therapeutic opportunities and challenges of utilizing kinase inhibitors in chronic immune and inflammatory diseases.
  • To explore the potential for developing selective kinase inhibitors for non-oncologic applications.
  • To assess the requirements for enhanced kinase selectivity in treating immune-mediated conditions.

Main Methods:

  • Literature review of marketed kinase inhibitors and their targets.
  • Analysis of selectivity profiles of existing kinase inhibitors.
  • Discussion of the implications of kinase inhibition for immune and inflammatory pathways.

Main Results:

  • Kinase inhibitors have successfully demonstrated targeted therapy in oncology.
  • Achieving sufficient selectivity for immune and inflammatory targets presents a significant challenge.
  • The broader kinome presents a complex target landscape for immune-related diseases.

Conclusions:

  • Kinase inhibition offers a promising therapeutic avenue for chronic immune and inflammatory diseases.
  • Enhanced selectivity is paramount for successful application in non-oncologic indications.
  • Further research is needed to overcome selectivity challenges and optimize kinase inhibitor development for immune and inflammatory conditions.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...